cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Pieris Pharmaceuticals Inc
26 own
48 watching
Current Price
$16.42
$-0.38
(-2.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
17M
52-Week High
52-Week High
23.20000
52-Week Low
52-Week Low
6.20000
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization17M
icon52-Week High23.20000
icon52-Week Low6.20000
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Pieris Pharmaceuticals Inc do?
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
Read More
How much money does Pieris Pharmaceuticals Inc make?
News & Events about Pieris Pharmaceuticals Inc.
Accesswire
1 year ago
BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other conditions, today announced that...
Accesswire
1 year ago
BOSTON, MA / ACCESSWIRE / November 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced...
Accesswire
1 year ago
BOSTON, MA / ACCESSWIRE / November 9, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that...
Accesswire
1 year ago
BOSTON, MA / ACCESSWIRE / November 1, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced...
Zolmax
2years ago
Woodline Partners LP bought a new stake in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS Get Rating) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 2,463,641 shares of the biotechnology companys stock, valued at approximately $9,313,000. Other large investors ...
Frequently Asked Questions
Frequently Asked Questions
What is Pieris Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Pieris Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Pieris Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Pieris Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Pieris Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Pieris Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Pieris Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Pieris Pharmaceuticals Inc?
plus_minus_icon
What percentage is Pieris Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Pieris Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$16.42
$-0.38
(-2.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$92.40
$0.90 (0.98 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$3.75
$-0.29 (-7.28 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$4.03
$-0.04 (-0.98 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$1.74
$-0.08 (-4.40 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$92.40
$0.90 (0.98 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$3.75
$-0.29 (-7.28 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$4.03
$-0.04 (-0.98 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$1.74
$-0.08 (-4.40 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00